Business
Cryoport to Present at the J.P. Morgan 40th Annual Healthcare Conference
NASHVILLE, Tenn., Jan. 5, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply
About this update from Cryoport, Inc.
[{"type":"text","content":"NASHVILLE, Tenn., Jan. 5, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (\"Cryoport\" or the \"Company\"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Jerrell Shelton, the Company's Chief Executive Officer and Robert Stefanovich, the Company's Chief Financial Officer will be presenting at the J.P. Morgan 40th Annual Healthcare conference taking place virtually from January 10 - 13, 2022. Mr. Shelton will be presenting on Wednesday, January 12, 2022, at 9:00 a.m. ET. Additionally, Mr. Shelton, Mr. Stefanovich, and Thomas Heinzen, Vice President of Investor Relations and Corporate Development will be participating in 1x1 virtual meetings with attendees during the conference.\n\n \n \n \n \n \n \n\n \nAt the appointed time, interested parties may listen to Mr. Shelton's presentation by clicking here. The webcast can also be accessed from the Company's website www.cryoport.com in the Investor Relations section under Events & Presentations. The webcast replay will be available for 30 days following the live event.\nAbout Cryoport, Inc.\nCryoport, Inc. (Nasdaq: CYRX), headquartered in Nashville, TN, is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the clinical and commercial spectrum. With 33 strategic locations covering the Americas, EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Cryoport's global platform provides mission-critical solutions, services, and products to Biopharma, Reproductive Medicine, and Animal Health customers worldwide. In addition to its standard setting supply chain solutions, Cryoport is the world's largest manufacturer of cryogenic systems and one of the largest life science focused specialty couriers. As of September 30, 2021, Cryoport supported eight commercial cell and gene therapies and 582 regenerative medicine clinical trials in over 150 countries with 70 of these trials in Phase 3. \nFor more information, visit www.cryoport.com or follow @cryoport on Twitter at www.twitter.com/cryoport for live updates.\nForward Looking Statements\nStatements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, proje...